Statement Of Comprehensive Income [Abstract]

Innate Pharma - Filing #2811003

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Statement of comprehensive income [abstract]
Profit (loss)	— EUR	7 570 EUR	— EUR	7 570 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR
Other comprehensive income [abstract]
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	— EUR	394,000 EUR	394,000 EUR	— EUR	— EUR	— EUR	— EUR	— EUR	— EUR	790,000 EUR	790,000 EUR	— EUR	— EUR	— EUR	— EUR	— EUR
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Exchange differences on translation [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	— EUR	276,000 EUR	718,000 EUR	— EUR	994,000 EUR	— EUR	— EUR	— EUR	— EUR	428,000 EUR	428,000 EUR	— EUR	—	— EUR	— EUR	— EUR
Financial assets measured at fair value through other comprehensive income [abstract]
Other comprehensive income, net of tax, financial assets measured at fair value through other comprehensive income	—	— EUR	—	—	—	—	—	—	—	—	— EUR	—	—	—	—	—
Other comprehensive income	—	670,000 EUR	—	—	—	—	—	—	—	—	362,000 EUR	—	—	—	—	—
Comprehensive income	— EUR	6 900 EUR	324,000 EUR	7 570 EUR	994,000 EUR	— EUR	— EUR	— EUR	— EUR	362,000 EUR	57 741 EUR	— EUR	— EUR	58 103 EUR	— EUR	— EUR